8. Argenx SE (NASDAQ:ARGX)
Argenx SE (NASDAQ:ARGX) ranks among the most profitable biotech stocks to buy now. On April 14, TD Cowen maintained its Buy rating and $1,146 price target for Argenx SE (NASDAQ:ARGX), citing a quarterly monitoring poll that indicated first-quarter sales could outperform consensus projections. The firm’s fifth quarterly study of 30 neurologists treating patients with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy revealed persistent interest in the Vyvgart brand.
According to TD Cowen, Vyvgart’s first-quarter revenues will exceed the consensus expectation of $1,271 million, which is a 1% decrease from the previous quarter. The firm ascribed the predicted increase to the adoption of the Vyvgart Hytrulo prefilled syringe formulation.
According to the aforesaid study, the prefilled syringe formulation, which is still being used in both generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy diagnosis, was notably favored.
TD Cowen also voiced optimism about possible launches in ocular myasthenia gravis, for which a submission is expected shortly, and seronegative myasthenia gravis, which has a regulatory judgment date of May 10.
Argenx SE (NASDAQ:ARGX) is a biotech company that develops treatments for severe autoimmune diseases. The company operates through four segments: the United States, Japan, EMEA, and China.
7. Incyte Corporation (NASDAQ:INCY)
Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation (NASDAQ:INCY)’s Buy rating and $135 price target. The firm stated that Incyte’s povorcitinib could be administered in the early stages of hidradenitis suppurativa, rather than as a post-biologic oral alternative.
H.C. Wainwright mentioned a meeting with a hidradenitis suppurativa expert who oversees a clinic at Geisinger Health with about 700 patients rotating each year, with nearly 80% categorized as moderate to severe.
In a similar vein, Citizens JMP reaffirmed its Market Perform rating for Incyte Corporation (NASDAQ:INCY) following the presentation of revised clinical trial data at the AAD 2026 Congress. Incyte reported 54-week results from the Phase 3 STOP-HS1/HS2 studies, which evaluated povorcitinib in moderate-to-severe hidradenitis suppurativa.
The data demonstrated that effectiveness deepens gradually with increasing HiSCR50 rates in both the initial treatment and crossover groups. Citizens stated that it has grown more convinced that implementation across the current portfolio can overcome the $3 billion-plus ruxolitinib patent gap by the end of 2028.
Incyte Corporation (NASDAQ:INCY), an American global pharmaceutical company, operates as a market leader in developing treatments for patients suffering from various diseases, including cancer.
